Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension

Article metrics

Abstract

Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and reduce plasma glucose and blood pressure in subjects with type 2 diabetes1. Although these agents can bind and activate an orphan nuclear receptor, peroxisome proliferator-activated receptor gamma (PPARγ), there is no direct evidence to conclusively implicate this receptor in the regulation of mammalian glucose homeostasis2. Here we report two different heterozygous mutations in the ligand-binding domain of PPARγ in three subjects with severe insulin resistance. In the PPARγ crystal structure, the mutations destabilize helix 12 which mediates transactivation. Consistent with this, both receptor mutants are markedly transcriptionally impaired and, moreover, are able to inhibit the action of coexpressed wild-type PPARγ in a dominant negative manner. In addition to insulin resistance, all three subjects developed type 2 diabetes mellitus and hypertension at an unusually early age. Our findings represent the first germline loss-of-function mutations in PPARγ and provide compelling genetic evidence that this receptor is important in the control of insulin sensitivity, glucose homeostasis and blood pressure in man.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Two new mutations, P467L and V290M, in human PPARγ.
Figure 2: Functional properties of the P467L and V290M mutant receptors.
Figure 3: Pro?467 and Val?290 are important in defining the orientation of helix 12.

References

  1. 1

    Day,C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med. 16, 179–192 (1999).

  2. 2

    Spiegelman,B. M. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507–514 (1998).

  3. 3

    Hattersley,A. T. Maturity onset diabetes of the young; clinical heterogeneity explained by genetic heterogeneity. Diabetic Med. 15, 15–24 (1998).

  4. 4

    Flier,J. S. Syndromes of insulin resistance—from patient to gene and back again. Diabetes 41, 1207–1219 (1992).

  5. 5

    Krook,A. et al. Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes 43, 357–368 (1994).

  6. 6

    Whitehead,J. P. et al. Molecular scanning of the insulin receptor substrate 1 gene in subjects with severe insulin resistance. Diabetes 47, 837–839 (1998).

  7. 7

    Tontonoz,P., Hu,E. & Spiegelman,B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147–1156 (1994).

  8. 8

    Lehmann,J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270, 12953–12956 (1995).

  9. 9

    Willson,T. M. et al. The structure–activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J. Med. Chem. 39, 665–668 (1996).

  10. 10

    Matthews,D. R. et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).

  11. 11

    Danielian,P. S., White,R., Lees,J. A. & Parker,M. G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 11, 1025–1033 (1992).

  12. 12

    Chakravarti,D. et al. Role of CBP/P300 in nuclear receptor signalling. Nature 383, 99–103 (1996).

  13. 13

    Di Renzo,J. et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol. Cell. Biol. 17, 2166–2176 (1997).

  14. 14

    Mukherjee,R. et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407–410 (1997).

  15. 15

    Collingwood,T. N., Adams,M., Tone,Y. & Chatterjee,V. K. K. Spectrum of transcriptional dimerization and dominant negative properties of twenty different mutant thyroid hormone β receptors in thyroid hormone resistance syndrome. Mol. Endocrinol. 8, 1262–1277 (1994).

  16. 16

    Desbois,C. et al. A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors. Cell 67, 731–740 (1991).

  17. 17

    Nolte,R. T. et al. Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395, 137–143 (1998).

  18. 18

    Ristow,M. et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New Engl. J. Med. 339, 953–959 (1998).

  19. 19

    Adams,M. et al. Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272, 5128–5132 (1997).

  20. 20

    Beamer,B. A. et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 47, 1806–1808 (1998).

  21. 21

    Deeb,S. S. et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genet. 20, 284–287 (1998).

  22. 22

    Sarraf,P. et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol. Cell 3, 799–804 (1999).

  23. 23

    Libby,P. et al. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19, 546–551 (1999).

  24. 24

    Iijima,K. et al. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in rat aortic smooth muscle cells. Biochem. Biophys. Res. Comm. 247, 353–356 (1998).

  25. 25

    Ogihara,T., Rakugi,H., Ikegama,H. et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hyperten. 8, 316–320 (1995).

  26. 26

    Nakamura,Y. et al. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br. J. Pharmacol. 123, 675–682 (1998).

  27. 27

    Satoh,H. et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARγ on vascular endothelial function. Biochem. Biophys. Res. Comm. 254, 757–763 (1999).

  28. 28

    Doi,K. et al. PPARγ modulates endothelial function: effects of thiazolidinediones on endothelial cell growth and secretion of endothelin (ET) and C-type natriuretic peptide (CNP). Circulation 98, 192 (1998).

  29. 29

    Young,P. W. et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J. Pharmacol. Exp. Ther. 284, 751–759 (1998).

  30. 30

    Forman,B. M. et al. 15-Dexoy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803–812 (1995).

Download references

Acknowledgements

M. Gurnell is a Wellcome Training Fellow, and S. O'Rahilly and K. Chatterjee are supported by the Wellcome Trust. We thank M. Flynn, A. Marshall and J. Keogh for assistance with clinical investigations, A. Rudenski for HOMA analysis, and S. Smith (SmithKline Beecham) for PPAR γ ligands. Among the many people at Incyte Europe involved in this project, we thank C. Baynes and J. Lightning for sequencing, I. Loudon for project management support; P. Weller and E. Génin for paternity testing and analysis, and C. Luccarini and D. Townley for PPARγ genomic structure determination.

Author information

Correspondence to S. O'Rahilly.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barroso, I., Gurnell, M., Crowley, V. et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880–883 (1999) doi:10.1038/47254

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.